New stuff on slides 14 and 15 from today's presentation. Most everything else is old. Slide 6 still shows a plan of first US Patient to be randomized in BETonMACE in Q1 2018, though last week's update gave a broader H1 2018 timeframe. I'll add the presentation to the link library too.

Slide 14 "Screening and Baseline Clinical Chemistry As of December 4, 2017" gives baseline data for most of their secondary outcome measures. Of note, looks like median HDL-C is 33 mg/dL, median fasting glucose is 135 mg/dL, median HbA1c% is 7.3 and median hsCRP is 2.9 mg/L, so as expected we have a low-HDL, diabetic, elevated hsCRP population. Also of note, BETonMACE population is 75.6% males and 52% of patients are on atorvastatin (Lipitor) and 48% on rosuvastatin (Crestor).

Slide 15 "BETonMACE Current Highlights" indicates that for the CKD Subgroup there are 11% of patients with eGFR<60 at screening, and for the Cognition Subgroup there are 18% of patients that have completed the MoCA at Baseline (Target patients are those with baseline MoCA < 25). 

BearDownAZ